Brady Todd C purchased $418K of ALDX

Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the Division of Ophthalmology (the “DO”) of the U.S. Food and Drug Administration (the “FDA”) submit a review jurisdiction

Rayner's RayOne Galaxy IOLs received FDA approval. Aldeyra plans to appeal FDA's rejection of reproxalap for dry eye disease. Sydnexis' SYD-101 for myopia will be reviewed at an FDA Advisory Committee meeting. Kodiak Sciences reported positive Phase 3 trial results for Zenkuda and KSI-501 in wet AMD. 4D Molecular Therapeutics began a Phase 3 trial for DME treatment with 4D-150. A study found a 16.1% increase in corneal transplants over 10 years, but supply-demand gap remains severe.

Aldeyra Therapeutics (ALDX) shares rose 13.79% after the company announced plans to submit a formal dispute resolution request to the FDA regarding its reproxalap program for dry eye disease. The FDA previously issued a Complete Response Letter citing insufficient evidence of efficacy. The move is seen as company-specific rather than sector-wide.

A pooled analysis of two trials found that reproxalap eye drops reduced dry eye symptoms more than a vehicle drop, with benefits seen in the first week. The most common side effect was irritation at the drop site. The study was funded by Aldeyra Therapeutics and published in Ophthalmology and Therapy.

Aldeyra Therapeutics, Inc. (ALDX) filed an SEC Form 8-K — Other Events. Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update CONFERENCE CALL September 29, 2026 Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2026 Exhibit 99.1 Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the

Aldeyra Therapeutics said it is reviewing FDA feedback on its dry eye drug reproxalap after receiving a CRL. CEO Brady said the FDA cited five trials, with disagreement on three; Aldeyra may use the FDA’s Formal Dispute Resolution process. He estimated any extra dry-eye trials could cost ≤$5M each. Aldeyra reported $65M cash and expects runway into H2 2028.